ReviewCureus2025
Association Between the Serum Uric Acid to Albumin Ratio and the No-Reflow Phenomenon After Percutaneous Coronary Intervention (PCI): A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The no-reflow phenomenon (NR) following percutaneous coronary intervention (PCI) is an unpredictable complication linked to increased in-hospital mortality and adverse cardiovascular outcomes. Reliable predictors of NR remain unclear. This systematic review and meta-analysis aimed to evaluate the association between serum uric acid to albumin ratio (UAR) and NR development after PCI. A comprehensive search of MEDLINE, Cochrane, and EMBASE databases identified observational studies assessing this relationship. Studies that provided multivariate regression analyses to determine whether UAR is an independent predictor of NR were included, and pooled odds ratios (OR) were calculated using random effects models. Three studies with a total of 2,199 patients were included. The pooled analysis demonstrated a significant association between higher UAR and an increased risk of NR (OR: 3.04; 95% CI: 2.26-4.10; p < 0.00001; I² = 0%). These findings indicate that a higher serum UAR is independently associated with NR development and may serve as a useful, easily measurable predictor in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.